Bellerophon Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€4.84M - Cost of goods sold
€5.15K - Gross profit
€4.83M - SG&A expenses
€5.98M - R&D expenses
€8.33M - EBITDA
-€9.40M - D&A
€5.15K - EBIT
-€9.47M - Interest expenses
€75.50K - EBT
-€9.03M - Tax expenses
€874.23K - Net income
-€10.01M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€124.41K - Changes in working capital
-€3.03M - Operating cash flow
-€10.59M - Capex
€0.00 - Other investing cash flow
€0.00 - Net investing cash flow
€120.12K - Total cash dividends paid
€0.00 - Issuance of common stock
€1.26M - Debt repayment
€0.00 - Other financing cash flow
€3.06M - Net financing cash flow
€4.30M - Foreign exchange effects
€0.00 - Net change in cash
-€6.20M - Cash at end of period
€3.85M - Free cash flow
-€10.59M
Balance sheet
- Cash and cash equivalents
€3.76M - Cash and short-term investments
€3.76M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€512.23K - Total current assets
€4.27M - Property, plant & equipment
€0.00 - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€0.00 - Total assets
€4.27M - Accounts payable
€525.10K - Short-term debt
€0.00 - Other current liabilities
€552.55K - Total current liabilities
€1.08M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€0.00 - Total liabilities
€1.08M - Common stock
€104.68K - Retained earnings
-€219.92M - Other equity
€0.00 - Total equity
€3.19M - Total liabilities and shareholders' equity
€4.27M
Company information
- Market capitalization
€125.21K - Employees
18 - Enterprise Value
-€6.57M
Company ratios
- Gross margin
-
99.9% Much worse than peer group: 15,948,733,090,704,058,000.0% - EBITDA margin
-
-194.3% Much worse than peer group: 1,539,952,135,862,247,600.0% - EBIT margin
-
-195.7% Much worse than peer group: 1,320,453,048,200,717,600.0% - EBT margin
-
-186.7% Much worse than peer group: 1,613,668,243,531,197,600.0% - Net margin
-
-206.9% Much worse than peer group: 1,613,668,243,531,198,800.0% - ROE
-
-313.5% Much better than peer group: -511.6% - ROA
-
-234.4% Much better than peer group: -1,490.2% - Asset turnover
-
113.3% Much worse than peer group: 402.8% - FCF margin
-
-218.8% Much worse than peer group: 914,129,733,634,477,400.0% - FCF yield
-8,455.6% - Efficiency ratio
294.3% - Net sales per employee
-
€268.84K - Net income per employee
-
-€556.27K